Sermorelin vs Ipamorelin: Which Growth Hormone Peptide Is Right for You?

Both stimulate growth hormone release, but they work differently. We break down the evidence on efficacy, cost, and who each is best for.

Both sermorelin and ipamorelin are growth hormone secretagogues — compounds that stimulate the pituitary gland to produce and release growth hormone. But they work through different mechanisms, have different dosing schedules, and are suited to different patient profiles.

Sermorelin is a GHRH analog, meaning it mimics the natural growth hormone-releasing hormone produced by your hypothalamus. It directly stimulates the pituitary gland's GHRH receptors. Because it works through the same pathway as natural GHRH, sermorelin maintains the body's natural feedback loops, making it a very physiologically appropriate option for GH optimization.

Ipamorelin is a GHRP (growth hormone releasing peptide) and ghrelin receptor agonist. It works through a different pathway — the ghrelin receptor system — to stimulate GH release. What distinguishes ipamorelin from older GHRPs is its high selectivity: it stimulates GH release without significantly affecting cortisol, prolactin, or other hormones, making it one of the cleanest GH-releasing peptides available.

In practice, these two peptides are frequently combined. The CJC-1295/Ipamorelin stack (CJC-1295 is a long-acting GHRH analog similar to sermorelin) has become one of the most popular peptide protocols in telehealth. The combination works synergistically to produce amplified GH pulses by stimulating both the GHRH and ghrelin pathways simultaneously.

For cost-conscious patients starting out, sermorelin is typically less expensive and represents an excellent entry point into GH optimization. For those seeking a more comprehensive protocol or who have used sermorelin before, the ipamorelin stack is often the natural next step.

Providers offering these peptides